<p>随着全球市场在利率决策和经济指标的预期中航行，亚洲股市因其独特的动态而备受关注。在这些发展中，识别潜在被低估的股票可以为希望利用市场价格与内在价值之间差异的投资者提供有趣的机会。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安诺瓦星云科技（SZSE:301589）</td>
<td>CN¥153.53</td>
<td>CN¥302.13</td>
<td>49.2%</td>
</tr>
<tr>
<td>武汉港迪技术（SZSE:002414）</td>
<td>CN¥12.58</td>
<td>CN¥25.14</td>
<td>50%</td>
</tr>
<tr>
<td>Last One Mile 有限公司（TSE:9252）</td>
<td>¥3490.00</td>
<td>¥6861.35</td>
<td>49.1%</td>
</tr>
<tr>
<td>KIYO Learning 有限公司（TSE:7353）</td>
<td>¥694.00</td>
<td>¥1385.64</td>
<td>49.9%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERING 有限公司（KOSDAQ:A036930）</td>
<td>₩28750.00</td>
<td>₩57013.96</td>
<td>49.6%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥5530.00</td>
<td>¥10925.89</td>
<td>49.4%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥12610.00</td>
<td>¥24483.73</td>
<td>48.5%</td>
</tr>
<tr>
<td>H.U. Group Holdings（TSE:4544）</td>
<td>¥3369.00</td>
<td>¥6592.59</td>
<td>48.9%</td>
</tr>
<tr>
<td>FIT Hon Teng（SEHK:6088）</td>
<td>HK$5.78</td>
<td>HK$11.23</td>
<td>48.5%</td>
</tr>
<tr>
<td>北京北摩高科技摩擦材料有限公司（SZSE:002985）</td>
<td>CN¥28.05</td>
<td>CN¥55.78</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 279 只被低估亚洲股票的完整列表。</p>
<p>我们将查看我们筛选工具中的一些最佳选择。</p>
<h2>Morimatsu International Holdings（SEHK:2155）</h2>
<p><strong>概述：</strong> Morimatsu International Holdings 有限公司专注于设计、制造、安装、运营和维护化学反应、生物反应和聚合的核心设备和工艺系统，市值为 106 亿港元。</p>
<p><strong>运营：</strong> 公司的收入主要来自综合压力设备的销售，金额为 61.6 亿人民币。</p>
<p><strong>公允价值折扣估计：</strong> 47.3%</p>
<p>Morimatsu International Holdings 的交易价格为 8.51 港元，远低于其估计的公允价值 16.14 港元，表明其基于现金流的估值极具吸引力。尽管过去一个季度内部人士有减持，但预计其收益在未来三年将以 23% 的年率增长，超过收入增长和香港市场的平均水平。然而，其股本回报率在三年内仍然温和，预计为 16.6%。</p>
<ul>
<li>我们对 Morimatsu International Holdings 的专业增长报告暗示其未来财务前景可能强于近期业绩。</li>
<li>通过阅读我们的健康报告，深入了解 Morimatsu International Holdings 的资产负债表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:2155 截至 2025 年 12 月的折现现金流</p>
<h2>浙江乔利制药有限公司（SZSE:300181）</h2>
<p><strong>概述：</strong> 浙江乔利制药有限公司专注于中药产品的研究、生产和营销，业务覆盖国内外，市值为 122.7 亿人民币。</p>
<p><strong>运营：</strong> 浙江乔利制药有限公司通过其在国内外市场的中药产品研究、生产和营销产生收入。</p>
<p><strong>公允价值折扣估计：</strong> 45.5%</p>
<p>浙江乔利制药有限公司的交易价格为 17.7 元，显著低于其估计的公允价值 32.5 元。尽管 3.39% 的股息收益率未能很好地覆盖自由现金流，但公司显示出 22.4% 的强劲收入增长，超过中国市场的平均增长率。最近的财务数据显示，2025 年前九个月销售和净收入均有所增加，尽管非现金收益水平较高，但基本面依然强劲。</p>
<ul>
<li>我们的增长报告表明浙江乔利制药有限公司可能面临改善的前景。</li>
<li>通过我们的全面财务健康报告，深入了解浙江乔利制药有限公司的复杂情况。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:300181 截至 2025 年 12 月的折现现金流</p>
<h2>青岛百合医疗（SZSE:301015）</h2>
<p><strong>概述：</strong> 青岛百合医疗有限公司涉及药品的研究、开发、生产、批发和零售，业务覆盖中国、美国、香港和英国，市值为 123.2 亿人民币。</p>
<p><strong>运营：</strong> 公司的收入来源于其在中国、美国、香港和英国等多个地区的药品研究、开发、生产、批发和零售活动。</p>
<p><strong>公允价值折扣估计：</strong> 14.0%</p>
<p>青岛百合医疗的交易价格为 23.44 元，相较于其公允价值估计 27.26 元被低估。尽管 2025 年前九个月销售和净收入有所下降，但预计公司在未来三年内的收益将显著增长，尽管增速低于市场平均水平。它在行业内提供良好的相对价值，并预计未来的股本回报率将达到 27.2%。</p>
<ul>
<li>我们的青岛百合医疗增长报告中的分析暗示未来财务表现强劲。</li>
<li>在我们的报告中更详细地了解青岛百合医疗的资产负债表健康状况。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:301015 截至 2025 年 12 月的折现现金流</p>
<h2>利用机会</h2>
<ul>
<li>点击这里解锁我们基于现金流的 279 只被低估亚洲股票的完整列表。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>使用 Simply Wall St 的免费应用程序简化您的投资策略，并从全球各地的股票研究中受益。</li>
</ul>
<h2>想探索一些替代方案吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以提供可靠的收入来源，以应对潜在的市场动荡。</li>
<li>通过显示强劲增长潜力的公司来增强您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

诺瓦星云

港迪技术

<p>亚洲股市因其独特的动态而受到关注，全球市场正在期待利率决策和经济指标的发布。识别被低估的股票为投资者提供了机会。基于现金流的顶级被低估股票包括西安诺瓦星云科技、武汉港迪技术、Last One Mile Ltd、KIYO Learning Ltd、JUSUNG ENGINEERING Ltd、JINS HOLDINGS、Ibiden Ltd、H.U. Group Holdings、FIT Hon Teng 和北京北摩高科技摩擦材料有限公司。森松国际控股、浙江乔利制药和青岛百合医疗因其显著的公允价值折扣而受到关注</p>

<p>As global markets navigate the anticipation of interest rate decisions and economic indicators, Asia's stock markets are drawing attention for their unique dynamics. Amidst these developments, identifying stocks that are potentially undervalued can offer intriguing opportunities for investors looking to capitalize on discrepancies between market prices and intrinsic values.</p>
<div class="lb-trans"><p>随着全球市场在利率决策和经济指标的预期中航行，亚洲股市因其独特的动态而备受关注。在这些发展中，识别潜在被低估的股票可以为希望利用市场价格与内在价值之间差异的投资者提供有趣的机会。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an NovaStar Tech (SZSE:301589)</td>
<td>CN¥153.53</td>
<td>CN¥302.13</td>
<td>49.2%</td>
</tr>
<tr>
<td>Wuhan Guide Infrared (SZSE:002414)</td>
<td>CN¥12.58</td>
<td>CN¥25.14</td>
<td>50%</td>
</tr>
<tr>
<td>Last One MileLtd (TSE:9252)</td>
<td>¥3490.00</td>
<td>¥6861.35</td>
<td>49.1%</td>
</tr>
<tr>
<td>KIYO LearningLtd (TSE:7353)</td>
<td>¥694.00</td>
<td>¥1385.64</td>
<td>49.9%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERINGLtd (KOSDAQ:A036930)</td>
<td>₩28750.00</td>
<td>₩57013.96</td>
<td>49.6%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥10925.89</td>
<td>49.4%</td>
</tr>
<tr>
<td>IbidenLtd (TSE:4062)</td>
<td>¥12610.00</td>
<td>¥24483.73</td>
<td>48.5%</td>
</tr>
<tr>
<td>H.U. Group Holdings (TSE:4544)</td>
<td>¥3369.00</td>
<td>¥6592.59</td>
<td>48.9%</td>
</tr>
<tr>
<td>FIT Hon Teng (SEHK:6088)</td>
<td>HK$5.78</td>
<td>HK$11.23</td>
<td>48.5%</td>
</tr>
<tr>
<td>Beijing Beimo High-tech Frictional MaterialLtd (SZSE:002985)</td>
<td>CN¥28.05</td>
<td>CN¥55.78</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>西安诺瓦星云科技（SZSE:301589）</td>
<td>CN¥153.53</td>
<td>CN¥302.13</td>
<td>49.2%</td>
</tr>
<tr>
<td>武汉港迪技术（SZSE:002414）</td>
<td>CN¥12.58</td>
<td>CN¥25.14</td>
<td>50%</td>
</tr>
<tr>
<td>Last One Mile 有限公司（TSE:9252）</td>
<td>¥3490.00</td>
<td>¥6861.35</td>
<td>49.1%</td>
</tr>
<tr>
<td>KIYO Learning 有限公司（TSE:7353）</td>
<td>¥694.00</td>
<td>¥1385.64</td>
<td>49.9%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERING 有限公司（KOSDAQ:A036930）</td>
<td>₩28750.00</td>
<td>₩57013.96</td>
<td>49.6%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥5530.00</td>
<td>¥10925.89</td>
<td>49.4%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥12610.00</td>
<td>¥24483.73</td>
<td>48.5%</td>
</tr>
<tr>
<td>H.U. Group Holdings（TSE:4544）</td>
<td>¥3369.00</td>
<td>¥6592.59</td>
<td>48.9%</td>
</tr>
<tr>
<td>FIT Hon Teng（SEHK:6088）</td>
<td>HK$5.78</td>
<td>HK$11.23</td>
<td>48.5%</td>
</tr>
<tr>
<td>北京北摩高科技摩擦材料有限公司（SZSE:002985）</td>
<td>CN¥28.05</td>
<td>CN¥55.78</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 279 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 279 只被低估亚洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看我们筛选工具中的一些最佳选择。</p>
</div><h2>Morimatsu International Holdings (SEHK:2155)</h2>
<div class="lb-trans"><h2>Morimatsu International Holdings（SEHK:2155）</h2>
</div><p><strong>Overview:</strong> Morimatsu International Holdings Company Limited specializes in designing, manufacturing, installing, operating, and maintaining core equipment and process systems for chemical reactions, biological reactions, and polymerization with a market cap of HK$10.60 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Morimatsu International Holdings 有限公司专注于设计、制造、安装、运营和维护化学反应、生物反应和聚合的核心设备和工艺系统，市值为 106 亿港元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from the sale of comprehensive pressure equipment, amounting to CN¥6.16 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自综合压力设备的销售，金额为 61.6 亿人民币。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 47.3%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 47.3%</p>
</div><p>Morimatsu International Holdings is trading at HK$8.51, significantly below its estimated fair value of HK$16.14, indicating it is highly undervalued based on cash flows. Despite insider selling in the past quarter, its earnings are projected to grow 23% annually over the next three years, outpacing both revenue growth and the Hong Kong market average. However, its return on equity remains modestly forecasted at 16.6% in three years.</p>
<div class="lb-trans"><p>Morimatsu International Holdings 的交易价格为 8.51 港元，远低于其估计的公允价值 16.14 港元，表明其基于现金流的估值极具吸引力。尽管过去一个季度内部人士有减持，但预计其收益在未来三年将以 23% 的年率增长，超过收入增长和香港市场的平均水平。然而，其股本回报率在三年内仍然温和，预计为 16.6%。</p>
</div><ul>
<li>Our expertly prepared growth report on Morimatsu International Holdings implies its future financial outlook may be stronger than recent results.</li>
<li>Get an in-depth perspective on Morimatsu International Holdings' balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们对 Morimatsu International Holdings 的专业增长报告暗示其未来财务前景可能强于近期业绩。</li>
<li>通过阅读我们的健康报告，深入了解 Morimatsu International Holdings 的资产负债表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf?theme=light"/></p>
<p>SEHK:2155 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SEHK:2155 截至 2025 年 12 月的折现现金流</p>
</div><h2>Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)</h2>
<div class="lb-trans"><h2>浙江乔利制药有限公司（SZSE:300181）</h2>
</div><p><strong>Overview:</strong> Zhejiang Jolly Pharmaceutical Co., LTD focuses on the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥12.27 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 浙江乔利制药有限公司专注于中药产品的研究、生产和营销，业务覆盖国内外，市值为 122.7 亿人民币。</p>
</div><p><strong>Operations:</strong> Zhejiang Jolly Pharmaceutical Co., LTD generates revenue through its research, production, and marketing of Chinese medicinal products in both domestic and international markets.</p>
<div class="lb-trans"><p><strong>运营：</strong> 浙江乔利制药有限公司通过其在国内外市场的中药产品研究、生产和营销产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 45.5%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 45.5%</p>
</div><p>Zhejiang Jolly Pharmaceutical Co., LTD, trading at CN¥17.7, is significantly undervalued with an estimated fair value of CN¥32.5. Despite a dividend yield of 3.39% not well covered by free cash flows, the company shows robust revenue growth at 22.4% annually, outpacing the Chinese market's average growth rate. Recent financials reveal increased sales and net income for the first nine months of 2025, underscoring strong fundamentals despite high non-cash earnings levels.</p>
<div class="lb-trans"><p>浙江乔利制药有限公司的交易价格为 17.7 元，显著低于其估计的公允价值 32.5 元。尽管 3.39% 的股息收益率未能很好地覆盖自由现金流，但公司显示出 22.4% 的强劲收入增长，超过中国市场的平均增长率。最近的财务数据显示，2025 年前九个月销售和净收入均有所增加，尽管非现金收益水平较高，但基本面依然强劲。</p>
</div><ul>
<li>Our growth report here indicates Zhejiang Jolly PharmaceuticalLTD may be poised for an improving outlook.</li>
<li>Navigate through the intricacies of Zhejiang Jolly PharmaceuticalLTD with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的增长报告表明浙江乔利制药有限公司可能面临改善的前景。</li>
<li>通过我们的全面财务健康报告，深入了解浙江乔利制药有限公司的复杂情况。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf?theme=light"/></p>
<p>SZSE:300181 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SZSE:300181 截至 2025 年 12 月的折现现金流</p>
</div><h2>Qingdao Baheal Medical (SZSE:301015)</h2>
<div class="lb-trans"><h2>青岛百合医疗（SZSE:301015）</h2>
</div><p><strong>Overview:</strong> Qingdao Baheal Medical INC. is involved in the research, development, production, wholesale, and retail of pharmaceutical products across China, the United States, Hong Kong, and the United Kingdom with a market cap of CN¥12.32 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 青岛百合医疗有限公司涉及药品的研究、开发、生产、批发和零售，业务覆盖中国、美国、香港和英国，市值为 123.2 亿人民币。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from its activities in research, development, production, wholesale, and retail of pharmaceutical products across multiple regions including China, the United States, Hong Kong, and the United Kingdom.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入来源于其在中国、美国、香港和英国等多个地区的药品研究、开发、生产、批发和零售活动。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 14.0%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 14.0%</p>
</div><p>Qingdao Baheal Medical, trading at CN¥23.44, is undervalued compared to its fair value estimate of CN¥27.26. Despite a decline in sales and net income for the first nine months of 2025, the company's earnings are projected to grow significantly over the next three years, though slower than the market average. It offers good relative value within its industry and anticipates high future return on equity at 27.2%.</p>
<div class="lb-trans"><p>青岛百合医疗的交易价格为 23.44 元，相较于其公允价值估计 27.26 元被低估。尽管 2025 年前九个月销售和净收入有所下降，但预计公司在未来三年内的收益将显著增长，尽管增速低于市场平均水平。它在行业内提供良好的相对价值，并预计未来的股本回报率将达到 27.2%。</p>
</div><ul>
<li>The analysis detailed in our Qingdao Baheal Medical growth report hints at robust future financial performance.</li>
<li>Take a closer look at Qingdao Baheal Medical's balance sheet health here in our report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的青岛百合医疗增长报告中的分析暗示未来财务表现强劲。</li>
<li>在我们的报告中更详细地了解青岛百合医疗的资产负债表健康状况。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf?theme=light"/></p>
<p>SZSE:301015 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SZSE:301015 截至 2025 年 12 月的折现现金流</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用机会</h2>
</div><ul>
<li>Unlock our comprehensive list of 279 Undervalued Asian Stocks Based On Cash Flows by clicking here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里解锁我们基于现金流的 279 只被低估亚洲股票的完整列表。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>使用 Simply Wall St 的免费应用程序简化您的投资策略，并从全球各地的股票研究中受益。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过稳健的分红支付者来多样化您的投资组合，以提供可靠的收入来源，以应对潜在的市场动荡。</li>
<li>通过显示强劲增长潜力的公司来增强您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

预计 2025 年 12 月亚洲股票的估值低于其内在价值